TSLP blocker reduced exacerbations in patients with severe asthma and comorbid nasal polyps
News
JCVI does not recommend COVID-19 vaccination for all 12 to 15-year-olds
UK’s chief medical officers will now provide ‘further advice’ on COVID-19 vaccination in this age group
PMGroup Worldwide Ltd and The Datateam Media Group welcome Samedan Ltd
Samedan joining PMGroup and PharmaTimes Media Ltd as part of The Datateam Media Group’s healthcare division
NICE recommends Novartis’ Cosentyx for children with severe psoriasis
The monoclonal antibody is designed to block IL-17A, a molecule involved in the psoriasis inflammatory response
Takeda’s blood cancer drug fails to achieve Phase III endpoint
Pevonedistat plus azacitidine did not meet primary endpoint of EFS
BMS opts-in on Evotec’s neurodegenerative medicine
Deal worth $20m plus potential $250m in milestone payments
Moderna submits its COVID-19 vaccine booster to the FDA
Trial showed ‘robust antibody responses’ against Delta variant
GSK’s shingles vaccine Shingrix gains UK license
Jab aimed at adults aged 50 years and older and those at increased risk
IQVIA launches AI-powered medical information contact centre
AI tech designed to improve patient and HCP experience
Heart failure med Jardiance scores MHRA approval
Marketing authorisation covers treatment of heart failure with reduced ejection fraction
JCVI advises booster COVID-19 jab for severely immunosuppressed
Offer is separate to potential booster programme
Early use of Uptravi reduces risk of disease progression in PAH patients
Phase III study finds risk reduced by 52% compared with control group
MHRA nod for AbbVie’s Rinvoq for adults and adolescents with eczema
Large-scale phase III study met all primary and secondary endpoints
NICE, Cochrane to collaborate on delivery of ‘living’ recommendations
Agreement will allow NICE to make ‘efficient and effective’ updates to recommendations in its guideline portfolio
Phase III data for Jardiance shows improvement in HFpEF patients
Data presented at ESC Congress 2021
